Digital Support for Supervised Exercise Therapy in Peripheral Arterial Disease (TrackPAD)
Supervised Exercise Therapy Using Mobile Health Technology in Patients With Peripheral Arterial Disease: Randomized Controlled Pilot Trial.
The individual restrictions of daily life for patients with PAD are more important than statistical facts for mortality and morbidity. Intermittent claudication causes a progressive reduction of the pain-free walking distance (PWD) as an expression of a worsening PAD. This decrease in physical capability results in a decline of mental health and relevantly reduces the patients' quality of life (QoL).
Supervised exercise therapy (SET) is a cornerstone in the conservative management of intermittent claudication and extends the PWD. Even though SET is easy to practice and highly cost effective, the adherence to perform SET on a regular base is rather low. The underuse of exercise can be partly explained by the lack of institutional resources, but also by both patients' and physicians' lack of interest in exercise.
Mobile health (mHealth) technologies increase the incentives and provide digital support for patients with PAD on several treatment levels. They might lead to a higher adherence to exercise training and offer new scopes in patient-centered healthcare, but so far studies show opposite results. Because app stores are flooded with health and fitness apps, specific support tools are highly desired by patients with PAD and PAD-specific solutions are missing so far. Based on this background, the investigators developed a smartphone app named TrackPAD to provide PAD-specific support for SET.
The TrackPAD pilot study was designed as a 2-armed randomized controlled trial and included patients with diagnosed and symptomatic PAD. Patients were randomized by the Center for Clinical Studies in Essen using the TENALEA software into 2 groups. The control group included participants with standard care and no further mobile intervention. The intervention group included participants with standard care and additional mHealth-based self-tracking of their physical activity using trackPAD.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Essen, Deutschland, 45147
- Department of Cardiology and Vascular Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Diagnosis of lower extremity PAD based on (and/or):
- ABI ≤ 0.9 in at least one legs
- Invasive or non-invasive imaging of stenotic lower extremity artery disease
- Endovascular or surgical revascularization of lower extremity artery
- PAD Fontaine Stage IIa/b
- Smartphone with possibility to use TrackPAD: Android ≥ 5.0 or IOS ≥ 11.0
- Written informed consent prior to any study procedures, including a specified follow-up evaluation
- Best-medical treatment in the last 2 months in accordance with standard guidelines
Exclusion Criteria:
- Wheelchair bound, use of walking aid or walking impairment due to another cause than PAD
- Below or above knee amputation
- Acute or critical limb ischemia
- PAD Fontaine Stage I or III / IV
- No German knowledge
- Severe cognitive dysfunction
- Congestive heart failure with NYHA III-IV symptoms
- Active congestive heart failure requiring the initiation or uptitration of diuretic therapy
- Angina pectoris with CCS class 3-4 symptoms or myocardial infarction or stroke in the last 3 months
- Active arrhythmia requiring the initiation or uptitration of anti-arrhythmic therapy
- Severe valve disease
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: intervention group
in addition to the usual therapy, the patients were given access to the trackPAD app
|
TrackPAD is a smartphone app to provide PAD-specific support for SET
|
|
Kein Eingriff: control group
patients in this group were treated as usual in the clinic without additional interventions.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
change in 6-minutes walking distance
Zeitfenster: baseline, 3 months follow-up
|
measured via GPS with the trackPAD app
|
baseline, 3 months follow-up
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
change in physical activity, measured in patients' self-report on how many days a week on average they engage in a physical activity that causes them to sweat or get out of breath, and how many minutes on average they spend doing it.
Zeitfenster: baseline, 3 months follow-up
|
to compare the two groups groups in terms of physical endurance, the self-reported physical activity was recorded
|
baseline, 3 months follow-up
|
|
peripheral arterial disease-related quality of life
Zeitfenster: baseline, 3 months follow-up
|
measured with the Peripheral artery disease Quality of Life Questionnaire (PADQOL) questionnaire, a validated PAD-specific questionnaire.
Minimum score is 38 and maximum is 228, with higher values indicating a better outcome.
|
baseline, 3 months follow-up
|
|
Usability of the TrackPAD app
Zeitfenster: baseline, 3 months follow-up
|
measured with the User version of the Mobile Application Rating Scale (uMars) questionnaire.
The uMARS includes 3 factors, namely app quality, app subjective quality and perceived impact.
Minimum score of the app quality scale is 4 and the maximum is 20.
The App Subjective Quality scale has a minimum of 4 and a maximum of 20, and the Perceived Impact scale has a minimum of 6 and a maximum of 30.
Higher values indicate a better outcome.
|
baseline, 3 months follow-up
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Julia Lortz, University Hospital, Essen
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Paldan K, Simanovski J, Ullrich G, Steinmetz M, Rammos C, Janosi RA, Moebus S, Rassaf T, Lortz J. Feasibility and Clinical Relevance of a Mobile Intervention Using TrackPAD to Support Supervised Exercise Therapy in Patients With Peripheral Arterial Disease: Study Protocol for a Randomized Controlled Pilot Trial. JMIR Res Protoc. 2019 Jun 26;8(6):e13651. doi: 10.2196/13651.
- Paldan K, Steinmetz M, Simanovski J, Rammos C, Ullrich G, Janosi RA, Moebus S, Rassaf T, Lortz J. Supervised Exercise Therapy Using Mobile Health Technology in Patients With Peripheral Arterial Disease: Pilot Randomized Controlled Trial. JMIR Mhealth Uhealth. 2021 Aug 16;9(8):e24214. doi: 10.2196/24214.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 18-8355-BO
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Periphere arterielle Verschlusskrankheit
-
Universitaire Ziekenhuizen KU LeuvenUniversity of Pittsburgh; Sheba Medical Center; Mount Sinai Hospital, Canada; Leiden... und andere MitarbeiterUnbekanntTwin Reversal Arterial Perfusion SyndromeSpanien, Deutschland, Israel, Belgien, Niederlande, Kanada, Vereinigte Staaten, Österreich, Frankreich, Italien, Vereinigtes Königreich
-
University of MiamiRekrutierungZwilling-zu-Zwilling-Transfusionssyndrom | Zwilling; Komplizierte Schwangerschaft | Twin Reversal Arterial Perfusion Syndrome | Monochoriale diamniotische Plazenta | Monochoriale monoamniotische PlazentaVereinigte Staaten
-
Boston Children's HospitalNoch keine RekrutierungSchwangerschaft bezogen | Mütterlich; Verfahren | Fötale Zustände | Twin Monochorionic Monoamniotische Plazenta | Zwilling-zu-Zwilling-Transfusionssyndrom | Twin Reversal Arterial Perfusion Syndrome | Wasa Previa | In-utero-Eingriff, der den Fötus oder das Neugeborene betrifft | Chorion; Abnormal | C...Vereinigte Staaten